Program
zalfermin
Also written as “NNC0194-0499”, “NNC0194-0499/Semaglutide A (40/3.20 mg/mL)” and “NNC0194-0499/Semaglutide A (40/0.33mg/mL)”.
In Novo Nordisk's own words, a long-acting FGF-21 analogue
. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 1, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 101 open or running | phase 2since May 7, 2024 | Jan 6, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 6, 2017First study: phase 1 study in Nutrition DisordersFirst studyNCT03015207 · 56 enrolled · United States
- Mar 9, 2018Phase 1 study in Nutrition DisordersNCT03479892 · 57 enrolled · United States
- Jan 21, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04722653 · 42 enrolled · Japan
- Feb 5, 20233 phase 1 studies in Non-alcoholic Fatty Liver DiseaseNCT05727644, NCT05742919, NCT05766709
- Jun 8, 2023Phase 1 study in Hepatic ImpairmentNCT05917938 · 33 enrolled · Germany, Poland, Slovakia
- Dec 14, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06188026 · 34 enrolled · Austria
- May 7, 2024Phase 2 study in Alcohol-related Liver DiseaseNCT06409130 · 270 enrolled · United States, Australia, Bulgaria and more
- Jun 29, 2025Phase 1 study in Diabetes Mellitus, Type 1NCT07087795 · 96 enrolled · Germany
TargetBeta
“a long-acting FGF-21 analogue”company filing, read by Claude · source
Other programs on FGF21
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efimosfermin alfa | GlaxoSmithKline | phase 3 | 10 |
| pegozafermin | 89bio-inc | phase 3 | 8 |
| efruxifermin | Novo Nordisk | phase 3 | 6 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07087795Diabetes Mellitus, Type 1 · Germany | 1 | Active, not recruiting | Sep 12, 2026 | 96 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Nov 21, 2025 | 270 |
| NCT06188026Non-alcoholic Fatty Liver Disease · Austria | 1 | Completed | Dec 30, 2024 | 34 |
| NCT05917938Hepatic Impairment · Germany, Poland, Slovakia | 1 | Completed | Dec 16, 2024 | 33 |
| NCT05766709Non-alcoholic Fatty Liver Disease · Canada | 1 | Completed | Jan 5, 2024 | 53 |
| NCT05742919Non-alcoholic Fatty Liver Disease · China | 1 | Completed | Jun 13, 2023 | 24 |
| NCT05727644Non-alcoholic Fatty Liver Disease · Germany | 1 | Completed | Nov 10, 2023 | 42 |
| NCT04722653Non-alcoholic Fatty Liver Disease · Japan | 1 | Completed | Apr 27, 2021 | 42 |
| NCT03479892Nutrition Disorders · United States | 1 | Completed | Jun 4, 2019 | 57 |
| NCT03015207Nutrition Disorders · United States | 1 | Completed | Oct 26, 2017 | 56 |
How it is read
Names in the registry
- “NNC0194-0499”, 11 entries
- “NNC0194-0499/Semaglutide A (40/3.20 mg/mL)”, 1 entry
- “NNC0194-0499/Semaglutide A (40/0.33mg/mL)”, 1 entry
Codes read as this program: NNC01940499.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Obesity, 2 studies
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.